Class information for:
Level 2: CHRONIC MYELOID LEUKEMIA//IMATINIB//BCR ABL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
989 10020 42.5 82%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 3)


ID, lev.
above		 Publications Label for level above
100 72119 HER 2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA

Classes in level below (level 1)


ID, lev. below Publications Label for level below
384 3482 CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB
3520 1888 C FGR//TYROSINE PROTEIN KINASE//CSK
4600 1684 MSSP//C MYC PROTEIN//ONCOGENE RESEARCH
7452 1286 C ABL//BCR ABL//BCR ABL ONCOPROTEIN
9616 1070 C MYB//B MYB//V MYB
20833 383 V ERB B//V ERBB//ACUTE RETROVIRUS
25691 227 C FES//FER KINASE//FPS FES

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHRONIC MYELOID LEUKEMIA Author keyword 500 44% 9% 853
2 IMATINIB Author keyword 398 38% 8% 833
3 BCR ABL Author keyword 336 45% 6% 567
4 NILOTINIB Author keyword 330 70% 3% 273
5 DASATINIB Author keyword 235 54% 3% 305
6 CML Author keyword 150 29% 4% 429
7 C MYB Author keyword 99 54% 1% 129
8 CHRONIC MYELOGENOUS LEUKEMIA Author keyword 89 29% 3% 256
9 IMATINIB MESYLATE Author keyword 87 32% 2% 227
10 IMATINIB RESISTANCE Author keyword 86 66% 1% 79

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CHRONIC MYELOID LEUKEMIA 500 44% 9% 853 Search CHRONIC+MYELOID+LEUKEMIA Search CHRONIC+MYELOID+LEUKEMIA
2 IMATINIB 398 38% 8% 833 Search IMATINIB Search IMATINIB
3 BCR ABL 336 45% 6% 567 Search BCR+ABL Search BCR+ABL
4 NILOTINIB 330 70% 3% 273 Search NILOTINIB Search NILOTINIB
5 DASATINIB 235 54% 3% 305 Search DASATINIB Search DASATINIB
6 CML 150 29% 4% 429 Search CML Search CML
7 C MYB 99 54% 1% 129 Search C+MYB Search C+MYB
8 CHRONIC MYELOGENOUS LEUKEMIA 89 29% 3% 256 Search CHRONIC+MYELOGENOUS+LEUKEMIA Search CHRONIC+MYELOGENOUS+LEUKEMIA
9 IMATINIB MESYLATE 87 32% 2% 227 Search IMATINIB+MESYLATE Search IMATINIB+MESYLATE
10 IMATINIB RESISTANCE 86 66% 1% 79 Search IMATINIB+RESISTANCE Search IMATINIB+RESISTANCE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 CHRONIC MYELOGENOUS LEUKEMIA 746 27% 24% 2414
2 CYTOGENETIC RESPONSES 555 73% 4% 424
3 CHRONIC MYELOID LEUKEMIA 495 23% 19% 1884
4 CHRONIC PHASE 490 51% 7% 685
5 BCR ABL 488 38% 10% 1030
6 PHILADELPHIA CHROMOSOME 416 41% 8% 800
7 PATIENTS RECEIVING IMATINIB 384 87% 2% 186
8 V MYB 297 73% 2% 227
9 CLINICAL RESISTANCE 224 61% 2% 236
10 DIAGNOSED CHRONIC PHASE 216 88% 1% 102

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ONCOGENE RESEARCH 15 27% 0% 47
2 CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY 13 11% 1% 113
3 CURRENT HEMATOLOGIC MALIGNANCY REPORTS 3 10% 0% 24

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 2013 153 137 96%
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet 2009 462 110 97%
The development of imatinib as a therapeutic agent for chronic myeloid leukemia 2005 653 134 78%
Standardized definitions of molecular response in chronic myeloid leukemia 2012 81 28 93%
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet 2011 99 80 99%
Translation of the Philadelphia chromosome into therapy for CML 2008 284 86 76%
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet 2006 504 145 84%
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia 2007 272 74 89%
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 2015 2 29 83%
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia 2007 271 72 85%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 LEUKEMIA 48 14% 3.1% 310
2 HEMATOPOIESE LEUCEM CIBLE THER EUT 24 91% 0.1% 10
3 IMMUNE RECOVERY SECT 15 88% 0.1% 7
4 SECT EXPT HAEMATOL HAEMOPOIET STEM CELLS 15 88% 0.1% 7
5 MED UNIV KLIN 3 13 38% 0.3% 28
6 HEMATOL ONCOL LA SERAGNOLI 13 44% 0.2% 22
7 ONCOL HEMATOL CELL THER Y 12 63% 0.1% 12
8 HEMATOL UNIT HELSINKI 11 56% 0.1% 14
9 BMT LEUKEMIA 10 61% 0.1% 11
10 HEMATOPOIET STEM CELL LEUKEMIA 10 40% 0.2% 20

Related classes at same level (level 2)


Rank Relatedness score Related classes
1 0.0000021715 TETRASPANIN//CD9//CD151
2 0.0000017912 ID 1//NRSF//MYC
3 0.0000015640 CELL TRANSFORMATION ASSAY//ONCOGENIC RAS P21//BHAS 42 CELLS
4 0.0000013244 MYELODYSPLASTIC SYNDROMES//ACUTE MYELOID LEUKEMIA//LEUKEMIA
5 0.0000008663 GASTROINTESTINAL STROMAL TUMOR//GIST//GASTROINTESTINAL STROMAL TUMORS
6 0.0000008448 EGR 1//C FOS//CREM
7 0.0000008199 PIM 2//TRANSLATIONALLY CONTROLLED TUMOR PROTEIN//TCTP
8 0.0000008130 METHYLSULFONYLMETHANE//LEUKEMIA CELL DIFFERENTIATION//N ACETYL S N METHYLCARBAMOYLCYSTEINE
9 0.0000008044 X LINKED AGAMMAGLOBULINEMIA//BRUTONS TYROSINE KINASE//BTK
10 0.0000006917 ETS 1//PU1//HEMANGIOBLAST